NCT06092580 is a Phase 1 clinical trial of AWT020 in Advanced Cancer, sponsored by Anwita Biosciences.

Who is sponsoring NCT06092580?

NCT06092580 is sponsored by Anwita Biosciences.

What drugs are being tested in NCT06092580?

Interventions in NCT06092580: AWT020.

What condition does NCT06092580 study?

NCT06092580 studies Advanced Cancer.

Is NCT06092580 still recruiting?

NCT06092580 is currently recruiting now. Last updated 2 September 2025.

Last reviewed 2025-09-02 · How we verify

NCT06092580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of AWT020 in Advanced Cancer

Recruiting now Phase 1 Last updated 2 September 2025

What this trial tests

Phase 1 trial testing AWT020 in Advanced Cancer in 60 participants. Currently enrolling.

Timeline

15 September 2023

Primary endpoint
30 June 2026

30 September 2026

Quick facts

Lead sponsor	Anwita Biosciences
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 September 2023
Primary completion	30 June 2026
Estimated completion	30 September 2026
Sites	4 locations across Australia

Drugs / interventions tested

AWT020 — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Anwita Biosciences — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of AWT020

Trials testing the same drug.

NCT06839105 — A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies · Phase 1 · recruiting

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06092580 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anwita Biosciences
Last refreshed: 2 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06092580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing